T2 Biosystems, Inc.
TTOO
$0.1255
-$0.006-4.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.68M | 7.16M | 7.18M | 7.19M | 11.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.68M | 7.16M | 7.18M | 7.19M | 11.00M |
| Cost of Revenue | 26.47M | 26.20M | 28.86M | 29.41M | 31.96M |
| Gross Profit | -18.79M | -19.03M | -21.69M | -22.21M | -20.96M |
| SG&A Expenses | 22.84M | 23.45M | 24.27M | 24.83M | 26.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.33M | 49.75M | 53.24M | 54.35M | 58.20M |
| Operating Income | -41.66M | -42.59M | -46.07M | -47.15M | -47.20M |
| Income Before Tax | -42.95M | -48.26M | -45.65M | -50.08M | -49.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.95 | -48.26 | -45.65 | -50.08 | -49.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.95M | -48.26M | -45.65M | -50.08M | -49.84M |
| EBIT | -41.66M | -42.59M | -46.07M | -47.15M | -47.20M |
| EBITDA | -41.40M | -42.13M | -45.40M | -46.29M | -46.16M |
| EPS Basic | -5.94 | -8.82 | -16.03 | -145.14 | -279.43 |
| Normalized Basic EPS | -3.71 | -5.16 | -9.66 | -87.24 | -169.72 |
| EPS Diluted | -5.94 | -8.82 | -16.03 | -145.14 | -279.43 |
| Normalized Diluted EPS | -3.71 | -5.16 | -9.66 | -87.24 | -169.72 |
| Average Basic Shares Outstanding | 42.05M | 28.64M | 15.35M | 10.39M | 5.50M |
| Average Diluted Shares Outstanding | 42.05M | 28.64M | 15.35M | 10.39M | 5.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
